Modified fecal transplantation

Journal of Clinical Gastroenterology

Volumn 45, Issue 8, 2011, Pages 742-

  Martin, Liam ^a  

^a Willana Lifesciences Ashburn House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; FECAL TRANSPLANTATION; FECES ANALYSIS; HOSPITALIZATION; LETTER; PATIENT SAFETY; PRIORITY JOURNAL; TRANSPLANTATION;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; GASTROENTERITIS; HUMANS; INTESTINES;

EID: 80052022617     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182166c8b     Document Type: Letter

References (4)

1. Ho N, Prasad V. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. J Clin Gastroenterol. 2011;45:379-380.
2. The FECAL trial. Fecal therapy to Eliminate Clostridium difficile Associated Longstanding diarrhoea. Netherlands Trial Register. NTR Number 1177 of 14 January 2008. http://www.trialregister.nl/ trialreg/admin/rctview.asp?TC= 1177.
3. Aspevall OL, Lundberg A, Burman LG, et al. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother. 2006;50:1890-1892.
4. Pelaez T, Alcala L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002; 46:1647-1650. (Pubitemid 34535177)